Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations (2018 - 2023)

Aclaris Therapeutics' Liabilities from Discontinued Operations history runs 6 years deep, the most recent figure standing at 2202000.0 for Q4 2023.

• On a quarterly basis, Liabilities from Discontinued Operations changed 0.0% year-over-year to 2202000.0 in Q4 2023; TTM through Dec 2023 was 2202000.0, a 0.0% change from a year earlier, with the FY2023 full-year figure at 2202000.0, changed 0.0% from the prior year.
• Liabilities from Discontinued Operations steadied at 2202000.0 in Q4 2023 per ACRS's latest filing, from 2202000.0 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 14501000.0 in Q3 2019 and bottomed at 2198000.0 in Q3 2021.
• The 5-year median for Liabilities from Discontinued Operations is 2202000.0 (2021), against an average of 3228666.67.
• Across the five-year window, Liabilities from Discontinued Operations jumped 238.79% in 2019 and slumped 77.24% in 2020, its largest moves.
• Year by year, Liabilities from Discontinued Operations stood at 4157000.0 in 2019, then retreated by 25.16% to 3111000.0 in 2020, then decreased by 29.22% to 2202000.0 in 2021, then changed by 0.0% to 2202000.0 in 2022, then changed by 0.0% to 2202000.0 in 2023.
• Per Business Quant, the three latest ACRS Liabilities from Discontinued Operations figures stand at 2202000.0 (Q4 2023), 2202000.0 (Q3 2023), and 2202000.0 (Q2 2023).